8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Mar 4, 2026·SEC
TScan Therapeutics, Inc.(TCRX)Earnings, Financials & Key Ratios
TCRX•NASDAQ
Price updated Jun 19, 2026
AboutTScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$10M+266.7%
- EBITDA-$133M-1.7%
- Net Income-$130M-1.8%
- EPS (Diluted)-1.00+12.3%
- Gross Margin72.24%-27.8%
- EBITDA Margin-1287.62%+72.3%
- Operating Margin-1315.38%+72.5%
- Net Margin-1256.81%+72.2%
- ROE-71.28%-9.5%
TCRX Key Insights
TScan Therapeutics, Inc. (TCRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 56.9%
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Profits declining 37.8% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 16.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TCRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TCRX Price & Volume
TScan Therapeutics, Inc. (TCRX) stock price & volume — 10-year historical chart
Loading chart...
TCRX Growth Metrics
TScan Therapeutics, Inc. (TCRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years56.92%
3 Years-8.63%
TTM106.65%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.46%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM11.93%
Return on Capital
10 Years-46.3%
5 Years-45.54%
3 Years-46.86%
Last Year-49.82%
TCRX Recent Earnings
TScan Therapeutics, Inc. (TCRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.22+0.0%
$0.22
Rev
$982,000-60.7%
$3M
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.18+33.3%
$0.27
Rev
$3M+5.4%
$2M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.28+20.0%
$0.35
Rev
$3M+29.4%
$2M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.28+0.0%
$0.28
Rev
$3M+65.4%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.22vs $0.22+0.0% | $982,000vs $3M-60.7% |
| Q2 2026 | Mar 4, 2026 | $0.18vs $0.27+33.3% | $3Mvs $2M+5.4% |
| Q4 2025 | Nov 12, 2025 | $0.28vs $0.35+20.0% | $3Mvs $2M+29.4% |
| Q3 2025 | Aug 12, 2025 | $0.28vs $0.28+0.0% | $3Mvs $2M+65.4% |
Based on last 12 quarters of dataView full earnings history →
TCRX Peer Comparison
TScan Therapeutics, Inc. (TCRX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 TCRT | 5.25M | 2.15 | -0.98 | -50% | -1369.67% | -165.94% | ||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 CABA | 463.08M | 2.84 | -1.73 | -131.58% | 0.24 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare TCRX vs Peers
TScan Therapeutics, Inc. (TCRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TCRX Income Statement
TScan Therapeutics, Inc. (TCRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 1.08M | 10.14M | 13.54M | 21.05M | 2.82M | 10.32M | 9.14M |
Revenue Growth % | - | - | 834.65% | 33.47% | 55.52% | -86.62% | 266.65% | 106.65% |
Cost of Goods Sold | 9.44M | 20.58M | 0 | 0 | 0 | 0 | 2.87M | 693K |
COGS % of Revenue | - | 1896.5% | - | - | - | - | 27.76% | - |
Gross Profit | -9.44M▲ 0% | -19.49M▼ 106.4% | 10.14M▲ 152.0% | 13.54M▲ 33.5% | 21.05M▲ 55.5% | 2.82M▼ 86.6% | 7.46M▲ 164.9% | 8.44M▲ 0% |
Gross Margin % | - | -1796.5% | 100% | 100% | 100% | 100% | 72.24% | 92.41% |
Gross Profit Growth % | - | -106.44% | 152.03% | 33.47% | 55.52% | -86.62% | 164.88% | - |
Operating Expenses | 4.77M | 6.74M | 58.78M | 80.17M | 114.51M | 137.64M | 143.27M | 137.15M |
OpEx % of Revenue | - | 621.29% | 579.65% | 592.32% | 544% | 4887.68% | 1387.62% | - |
Selling, General & Admin | 4.77M | 6.74M | 13.83M | 20.35M | 25.49M | 29.56M | 31.99M | 30.56M |
SG&A % of Revenue | - | 621.29% | 136.36% | 150.37% | 121.11% | 1049.68% | 309.81% | - |
Research & Development | 9.44M | 20.58M | 44.95M | 59.82M | 88.15M | 107.35M | 114.15M | 106.27M |
R&D % of Revenue | - | 1896.5% | 443.29% | 441.96% | 418.8% | 3812.14% | 1105.57% | - |
Other Operating Expenses | -9.44M | -20.58M | 0 | 0 | 862K | 728K | -2.87M | 315K |
Operating Income | -14.21M▲ 0% | -26.23M▼ 84.6% | -48.64M▼ 85.4% | -66.64M▼ 37.0% | -93.46M▼ 40.3% | -134.82M▼ 44.3% | -135.81M▼ 0.7% | -128.7M▲ 0% |
Operating Margin % | - | -2417.79% | -479.65% | -492.32% | -444% | -4787.68% | -1315.38% | -1408.73% |
Operating Income Growth % | - | -84.61% | -85.42% | -37% | -40.25% | -44.26% | -0.74% | - |
EBITDA | -13.69M | -25M | -45.31M | -61.5M | -88.1M | -130.71M | -132.95M | -125.82M |
EBITDA Margin % | - | -2304.42% | -446.83% | -454.37% | -418.53% | -4641.8% | -1287.62% | -1377.2% |
EBITDA Growth % | - | -82.62% | -81.23% | -35.72% | -43.25% | -48.37% | -1.71% | 7.6% |
D&A (Non-Cash Add-back) | 519K | 1.23M | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M | 2.88M |
EBIT | -14.21M | -26.23M | -48.63M | -65.05M | -85.46M | -123.85M | -135.81M | -122.69M |
Net Interest Income | 552K | 106K | 16K | 415K | 4.24M | 8.41M | 6.05M | 4.61M |
Interest Income | 552K | 106K | 16K | 1.59M | 8M | 12.06M | 8.82M | 7.18M |
Interest Expense | 0 | 0 | 0 | 1.18M | 3.76M | 3.65M | 2.77M | 1.4M |
Other Income/Expense | 552K | 106K | 16K | 415K | 4.24M | 7.32M | 6.05M | 4.4M |
Pretax Income | -13.66M▲ 0% | -26.13M▼ 91.3% | -48.63M▼ 86.1% | -66.22M▼ 36.2% | -89.22M▼ 34.7% | -127.5M▼ 42.9% | -129.77M▼ 1.8% | -124.31M▲ 0% |
Pretax Margin % | - | -2408.02% | -479.49% | -489.26% | -423.86% | -4527.66% | -1256.81% | -1360.61% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -13.66M▲ 0% | -26.13M▼ 91.3% | -48.63M▼ 86.1% | -66.22M▼ 36.2% | -89.22M▼ 34.7% | -127.5M▼ 42.9% | -129.77M▼ 1.8% | -124.31M▲ 0% |
Net Margin % | - | -2408.02% | -479.49% | -489.26% | -423.86% | -4527.66% | -1256.81% | -1360.61% |
Net Income Growth % | - | -91.29% | -86.11% | -36.19% | -34.73% | -42.91% | -1.78% | 5.46% |
Net Income (Continuing) | -13.66M | -26.13M | -48.63M | -66.22M | -89.22M | -127.5M | -129.77M | -124.31M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.53▲ 0% | -1.04▼ 96.2% | -2.03▼ 95.2% | -2.74▼ 35.0% | -1.36▲ 50.4% | -1.14▲ 16.2% | -1.00▲ 12.3% | -0.96▲ 0% |
EPS Growth % | - | -96.23% | -95.19% | -34.98% | 50.37% | 16.18% | 12.28% | 11.93% |
EPS (Basic) | -0.53 | -1.04 | -2.03 | -2.74 | -1.36 | -1.14 | -1.00 | - |
Diluted Shares Outstanding | 24.94M | 24.94M | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M | 129.91M |
Basic Shares Outstanding | 24.94M | 24.94M | 23.91M | 24.05M | 65.6M | 111.99M | 129.86M | 129.91M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TCRX Balance Sheet
TScan Therapeutics, Inc. (TCRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 42.38M | 36.45M | 165.65M | 124.13M | 194.24M | 292.72M | 152.41M | 132.77M |
Cash & Short-Term Investments | 41.76M | 34.79M | 161.41M | 120.03M | 192.04M | 290.11M | 152.41M | 128.06M |
Cash Only | 41.76M | 34.79M | 161.41M | 120.03M | 133.36M | 178.69M | 152.41M | 128.06M |
Short-Term Investments | 0 | 0 | 0 | 0 | 58.69M | 111.42M | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 4.25M | 4.1M | 2.19M | 2.61M | 0 | 4.71M |
Total Non-Current Assets | 7M | 13.29M | 22.45M | 74.96M | 77.91M | 78.4M | 76.38M | 69.22M |
Property, Plant & Equipment | 6.41M | 12.53M | 17.26M | 69.2M | 71.23M | 71.6M | 0 | 64.13M |
Fixed Asset Turnover | - | 0.09x | 0.59x | 0.20x | 0.30x | 0.04x | - | 0.18x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 5.2M | 5.04M | 0 | 0 | 5.03M | 10.06M |
Other Non-Current Assets | 595K | 761K | 0 | 725K | 6.68M | 6.8M | 71.35M | 5.1M |
Total Assets | 49.38M▲ 0% | 49.74M▲ 0.7% | 188.11M▲ 278.2% | 199.09M▲ 5.8% | 272.15M▲ 36.7% | 371.12M▲ 36.4% | 228.79M▼ 38.4% | 201.99M▲ 0% |
Asset Turnover | - | 0.02x | 0.05x | 0.07x | 0.08x | 0.01x | 0.05x | 0.04x |
Asset Growth % | - | 0.72% | 278.2% | 5.84% | 36.7% | 36.37% | -38.35% | -122.65% |
Total Current Liabilities | 2.4M | 17.45M | 21.34M | 17.3M | 29.82M | 35.96M | 18.7M | 19.97M |
Accounts Payable | 1.01M | 2.91M | 1.76M | 2.91M | 2.37M | 4.28M | 1.24M | 2.3M |
Days Payables Outstanding | 39.04 | 51.62 | - | - | - | - | 158.05 | 1.9K |
Short-Term Debt | 0 | 0 | 1.65M | 3.68M | 3.35M | 0 | 7.17M | 7.44M |
Deferred Revenue (Current) | 0 | 10.63M | 11.41M | 3.87M | 10.14M | 11.7M | 0 | 14.52M |
Other Current Liabilities | 31K | 1.67M | 3.92M | 2.48M | 5.9M | 6.92M | 10.29M | 8.59M |
Current Ratio | 17.69x | 2.09x | 7.76x | 7.17x | 6.51x | 8.14x | 8.15x | 6.65x |
Quick Ratio | 17.69x | 2.09x | 7.76x | 7.17x | 6.51x | 8.14x | 8.15x | 6.65x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 4.44M | 74.75M | 5.99M | 82.35M | 91.46M | 94.19M | 86.97M | 85.1M |
Long-Term Debt | 0 | 0 | 0 | 29.29M | 26.7M | 32.07M | 32.53M | 52.45M |
Capital Lease Obligations | 4.44M | 6.02M | 4.39M | 53.01M | 59.14M | 60.74M | 54.44M | 168.86M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 59.92M | 97K | 49K | 0 | 135K | 0 | 32.65M |
Total Liabilities | 6.84M | 92.2M | 27.33M | 99.66M | 121.28M | 130.15M | 105.67M | 105.07M |
Total Debt | 4.89M | 7.43M | 6.04M | 85.98M | 92.43M | 97.38M | 94.14M | 59.88M |
Net Debt | -36.88M | -27.36M | -155.36M | -34.04M | -40.93M | -81.31M | -58.27M | -68.17M |
Debt / Equity | 0.11x | - | 0.04x | 0.86x | 0.61x | 0.40x | 0.76x | 0.62x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.48x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.54x |
Interest Coverage | - | - | - | -55.31x | -22.73x | -33.90x | -49.05x | -87.57x |
Total Equity | 42.54M▲ 0% | -42.46M▼ 199.8% | 160.78M▲ 478.6% | 99.43M▼ 38.2% | 150.87M▲ 51.7% | 240.97M▲ 59.7% | 123.12M▼ 48.9% | 96.92M▲ 0% |
Equity Growth % | - | -199.81% | 478.64% | -38.15% | 51.73% | 59.72% | -48.91% | -170.69% |
Book Value per Share | 1.71 | -1.70 | 6.72 | 4.13 | 2.30 | 2.15 | 0.95 | 0.75 |
Total Shareholders' Equity | 42.54M | -42.46M | 160.78M | 99.43M | 150.87M | 240.97M | 123.12M | 96.92M |
Common Stock | 0 | 1K | 3K | 3K | 5K | 6K | 5K | 6K |
Retained Earnings | -17.41M | -43.53M | -92.16M | -158.38M | -247.6M | -375.1M | -504.86M | -533.53M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 51K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRX Cash Flow Statement
TScan Therapeutics, Inc. (TCRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -12.52M | -3.02M | -48.68M | -66.5M | -61.36M | -110.82M | -135.32M | -122.01M |
Operating CF Margin % | - | -278.62% | -480% | -491.34% | -291.5% | -3935.44% | -1310.6% | - |
Operating CF Growth % | - | 75.86% | -1510.22% | -36.62% | 7.74% | -80.62% | -22.1% | -24.48% |
Net Income | -13.66M | -26.13M | -48.63M | -66.22M | -89.22M | -127.5M | -129.77M | -124.31M |
Depreciation & Amortization | 519K | 1.23M | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M | 2.88M |
Stock-Based Compensation | 240K | 515K | 2.52M | 4.55M | 5.21M | 9.55M | 11.71M | 8.29M |
Deferred Taxes | 0 | 0 | -9.16M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 78K | 2K | 9.16M | 260K | -315K | -2.03M | -1.95M | 1.8M |
Working Capital Changes | 299K | 21.36M | -5.9M | -10.23M | 17.61M | 5.05M | -18.18M | -10.69M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 161K | 1.13M | 10K | 528K | -52K | 1.99M | -3.01M | -2.52M |
Cash from Investing | -1.25M | -4.24M | -9.94M | -4.22M | -60.76M | -52.61M | 109.37M | 95.77M |
Capital Expenditures | -1.25M | -4.24M | -9.94M | -4.22M | -3.15M | -3.83M | -4.41M | -2.94M |
CapEx % of Revenue | - | 390.6% | 98.03% | 31.22% | 14.95% | 135.83% | 42.68% | 32.24% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 34.81M | 288K | 189.67M | 29.36M | 135.44M | 208.76M | -336K | 189K |
Debt Issued (Net) | 0 | 0 | 0 | 29.35M | 0 | 15.31M | 0 | 0 |
Equity Issued (Net) | 34.81M | 288K | 189.38M | 193K | 42.41M | 33.13M | 264K | 264K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 191K |
Other Financing | 5K | 0 | 291K | -191K | 93.03M | 160.32M | -600K | -75K |
Net Change in Cash | 21.04M▲ 0% | -6.97M▼ 133.1% | 131.05M▲ 1979.4% | -41.37M▼ 131.6% | 13.33M▲ 132.2% | 45.33M▲ 240.2% | -26.28M▼ 158.0% | -26.05M▲ 0% |
Free Cash Flow | -13.77M▲ 0% | -7.26M▲ 47.3% | -58.62M▼ 707.3% | -70.73M▼ 20.7% | -64.5M▲ 8.8% | -114.65M▼ 77.7% | -139.73M▼ 21.9% | -124.96M▲ 0% |
FCF Margin % | - | -669.22% | -578.03% | -522.56% | -306.45% | -4071.27% | -1353.28% | -1367.74% |
FCF Growth % | - | 47.27% | -707.3% | -20.66% | 8.8% | -77.74% | -21.88% | -0.94% |
FCF per Share | -0.55 | -0.29 | -2.45 | -2.94 | -0.98 | -1.02 | -1.08 | -0.96 |
FCF Conversion (FCF/Net Income) | 0.92x | 0.12x | 1.00x | 1.00x | 0.69x | 0.87x | 1.04x | 1.01x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TCRX Key Ratios
TScan Therapeutics, Inc. (TCRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -64511.11% | -82.2% | -50.9% | -71.29% | -65.08% | -71.28% | -91.94% |
Return on Invested Capital (ROIC) | - | - | -141.16% | -79.96% | -75.01% | -90.74% | -144.2% |
Gross Margin | -1796.5% | 100% | 100% | 100% | 100% | 72.24% | 92.41% |
Net Margin | -2408.02% | -479.49% | -489.26% | -423.86% | -4527.66% | -1256.81% | -1360.61% |
Debt / Equity | - | 0.04x | 0.86x | 0.61x | 0.40x | 0.76x | 0.62x |
Interest Coverage | - | - | -55.31x | -22.73x | -33.90x | -49.05x | -87.57x |
FCF Conversion | 0.12x | 1.00x | 1.00x | 0.69x | 0.87x | 1.04x | 1.01x |
Revenue Growth | - | 834.65% | 33.47% | 55.52% | -86.62% | 266.65% | 106.65% |
Related:TCRX Dividend History·TCRX Revenue History·TCRX Price History·TCRX P/E History·TCRX Financial Ratios·TCRX Institutional Holders
TCRX SEC Filings & Documents
TScan Therapeutics, Inc. (TCRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TCRX Frequently Asked Questions
TScan Therapeutics, Inc. (TCRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TScan Therapeutics, Inc. (TCRX) reported $9.1M in revenue for fiscal year 2025.
TScan Therapeutics, Inc. (TCRX) grew revenue by 266.7% over the past year. This is strong growth.
TScan Therapeutics, Inc. (TCRX) reported a net loss of $124.3M for fiscal year 2025.
Dividend & Returns
TScan Therapeutics, Inc. (TCRX) has a return on equity (ROE) of -71.3%. Negative ROE indicates the company is unprofitable.
TScan Therapeutics, Inc. (TCRX) had negative free cash flow of $125.0M in fiscal year 2025, likely due to heavy capital investments.